Nurse Practitioner, Primary Care · Philadelphia, PA
NPI
1023555398
Since 2017
Specialty
Nurse Practitioner, Primary Care
Code 363LP2300X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
3400 Civic Center Blvd
Philadelphia, PA, 19104
Phone (215) 662-4000
Groups this clinician bills Medicare through
Medicare paid, 2024
$23K
579 services
Medicare patients, 2024
103
Average age 72
Drug cost, 2024
$5.2M
976 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alicia Rae McLeish was code 99214 (office e&m - established), 297 times for 96 patients. In total Alicia Rae McLeish billed 579 services in 5 codes, and Medicare paid $23K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-02-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 297 | 96 | $61.97 | $18K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 249 | 90 | $11.18 | $2,783 |
By year: 2022 $13K for 197 services; 2023 $16K for 248 services; 2024 $23K for 579 services.
Medicare prescription drug claims, 2024
In 2024, the drug Alicia Rae McLeish prescribed most often to Medicare patients was Calquence (Acalabrutinib Maleate), with 154 prescriptions and refills. In total Alicia Rae McLeish wrote 976 Medicare prescriptions that cost $5.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Calquence Acalabrutinib Maleate | 154 | 154 | 22 | $2.0M |
| Imbruvica Ibrutinib | 73 | 75 | 11 | $1.2M |
| Acyclovir Generic | 68 | 124 | 18 | $958 |
| Valacyclovir Valacyclovir Hcl | 40 | 80 | 19 | $3,129 |
| Brukinsa Zanubrutinib | 40 | 40 | 11 | $548K |
| Venclexta Venetoclax | 40 | 40 | Under 11 | $541K |
| Allopurinol Generic | 39 | 52 | 18 | $227 |
| Ondansetron Hcl Generic | 36 | 36 | 17 | $293 |
| Eliquis Apixaban | 30 | 39 | Under 11 | $23K |
| Gabapentin Generic | 30 | 58 | 13 | $313 |
| Prednisone Generic | 23 | 25 | 14 | $94.07 |
| Pantoprazole Sodium Generic | 22 | 26 | Under 11 | $149 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 21 | 37 | Under 11 | $126 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 19 | 19 | 14 | $172 |
| Dexamethasone Generic | 18 | 18 | Under 11 | $122 |
Brand drugs: - claims; generic drugs: 548 claims; opioid claims: 12.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Alicia Rae McLeish were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.